View Nicola Redfern's ProfileFollowing five years of experience working in the gene therapy arena, with a focus on reimbursement and commercialisation, Nicola set up NJ Redfern Ltd in 2022 to enable her to consult, coach and collaborate with other organisations, following her departure from bluebird bio in Europe.
With a consistent focus over recent decades on rare diseases & oncology/ haematology, her primary attention has been on pricing and reimbursement, service delivery and shaping the external environment. She has been in the pharmaceutical industry since 1989, joining from Martin House Childrens Hospice in Yorkshire, and has been employed by 10 different companies, and contracted with 13 to date, in a diverse range of roles – including supporting 2 further gene therapy companies in their launch planning in the UK. Nicola was previously an active member of the ABPI – chairing the ATMP working group during 2021, a member of their Value and Access group and supporting various government affairs/communications initiatives. She has worked closely in the last 6 years with the Cell and Gene therapy catapult in the UK.
More recently Nicola has been invited to sit on the advisory board for company ATMPS, is an advisor to the Hanover Communications team, has given talks at various ATMP congresses, has been interviewed by Lumanity and Haemnet, and since January 2023 has sat on the ethics subgroup of the International Society of Cell and Gene therapy and is a member of ATMP engage.
Nicola is committed to and motivated by patients having a choice and being able to access transformative treatment options quickly once science and innovation reach a point to positively impact the lives of people living with significant health challenges. Having sat on the board of trustees at Naomi House and Jacks Place – a Hospice for children and young adults near Winchester, UK – and through working alongside multiple patient organisations over her career, she has a strong empathy and understanding of life-limiting conditions and their impact on the individual, their families and society as a whole.
